1. Research Center and Department of Physiology, School of Medicine, Semnan University of Medical Sciences, Semnan, Iran 2. Research Center and Department of Physiology, School of Medicine, Semnan University of Medical Sciences, Semnan, Iran
Abstract
Introduction
The goal of the present study was to test the dose-dependent and time-dependent effects of mouse recombinant resistin in the recovery of stroke damage, brain edema, and neurological deficit in a mouse model of stroke.
Methods
Transient focal cerebral ischemia was induced by the middle cerebral artery occlusion (mcao) in mice. resistin at doses of 25, 50, 100, 200, and 400 ng/mouse, was administered intracerebroventricularly (icv) at the commencement of mcao. 24 h after inducing the ischemia, infarct size, brain edema and neurological function were assessed by using the standard methods.
Results
Central administration of resistin only at doses of 200 and 400 ng/mouse considerably reduced the infarct size and promoted neurological function (p < 0.001). in addition, resistin at the most effective dose (400 ng/mouse) significantly decreased brain edema (p < 0.001) at 24 h after ischemia. delivery of resistin up to 1 hour after the onset of cerebral ischemia was protective (p < 0.001).
Conclusion
Our findings revealed that treatment with the mouse recombinant resistin could attenuate ischemic damage in a dose-dependent approach in the early stages of focal cerebral ischemia. further studies are essential to clarify the role of resistin in the pathophysiology of cerebral ischemia and use it as a therapeutic target for the stroke patients.
